Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-6: Metformin in Outpatient COVID-19
NCT06042855Phase 3Completed
- Start
- Sep 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Metformin with Placebo (2 arms). Primary endpoints: Time to Sustained Recovery at 28 days and Number of Participants With Hospitalization or Death at 28 days. Started Sep 2023; status: completed.
02
Drugs
metformin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06042855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06042855.